Nexalin Technology CEO Mark White shared positive results from a clinical study evaluating the company’s Gen-2 tACS device for reducing pain in veteran patients with Mild Traumatic Brain Injury (mTBI). The study was conducted at The University of California, San Diego, in collaboration with the United States Department of Veterans Affairs San Diego Healthcare System, as well as the Radiology, Psychiatry, and Neurosciences Departments of UC San Diego.
The results of the clinical trial were significant, especially considering the substantial market potential for treatments addressing traumatic brain injuries. According to Global Market Insights, the Traumatic Brain Injuries Assessment Market is projected to reach over $7.2 billion by 2032. This highlights the importance of effective treatments for post-concussive symptoms (PCS), which are common in individuals with mTBI and can lead to various physical, cognitive, emotional, and behavioral deficits.
Nexalin’s innovative approach offers promise in addressing the needs of individuals suffering from mTBI, potentially improving their quality of life and providing hope for effective treatment options in the future. For more information about Nexalin Technology and its Gen-2 tACS device, please contact Proactive North America at +1 604-688-8158 or email NA-editorial@proactiveinvestors.com.
